The News Bee

Creative Biolabs Released PDCD1 Therapeutic Antibody Production Service

Creative Biolabs Released PDCD1 Therapeutic Antibody Production Service

Following the approval of Pembrolizumab by FDA, Creative Biolabs developed anti-human PDCD1 therapeutic antibody for scientists focused in the field of cancer research.

Creative Biolabs is a biotech supplier specialized in antibody products and related services. Over the last 10 years, it has been a leader of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields all over the world.

Anti-human PDCD1 therapeutic antibody is a humanized antibody used in cancer immunotherapy. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor, and is intended for use in treating metastatic melanoma.

In May 2017, pembrolizumab was approved by FDA for any unresectable or metastatic solid tumor with certain genetic qualities without regarding to the tissue type or site of the tumor, which is a first for the FDA. Since 2017, pembrolizumab has been used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a second-line treatment for head and neck squamous cell carcinoma (HNSCC) after platinum-based chemotherapy, as well as for the treatment of adult and pediatric patients with refractory classic Hodgkin’s lymphoma (cHL).

Learn more about PDCD1 antibody.

About Creative Biolabs

Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early antibody drug discovery and development. As a trusted provider of cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of satisfied clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world.

Its cutting-edge hybridoma development and phage display platforms allow the production of the most comprehensive list of recombinant antibody products and extensive service portfolio, ranging from antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor (CAR) products and antibody drug conjugate (ADC) to engineered antibodies, such as therapeutic antibodies, single-domain antibodies, bispecific antibodies, intrabodies, etc. 

Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: http://www.creativebiolabs.net

Calendar

November 2017
M T W T F S S
« Oct    
 12345
6789101112
13141516171819
20212223242526
27282930